PDF Cover

Glaucoma Surgery Devices Market

The market for Glaucoma Surgery Devices was estimated at $1.4 billion in 2024; it is anticipated to increase to $2.1 billion by 2030, with projections indicating growth to around $2.9 billion by 2035.

Report ID:DS1801697
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Glaucoma Surgery Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Glaucoma Surgery Devices Market Outlook

Revenue, 2024

$1.4B

Forecast, 2034

$2.7B

CAGR, 2025 - 2034

6.7%

The Glaucoma Surgery Devices industry revenue is expected to be around $1.5 billion in 2025 and expected to showcase growth with 6.7% CAGR between 2025 and 2034. The growing importance of glaucoma surgical equipment is a result of the need to stop glaucoma patients losing their sight and is also being driven by an increase in the number of people suffering from the disease and the ageing population; hospitals which account for 84.1% of theindustry'srevenue are rapidly introducing new glaucoma surgery equipment into their standard procedures, aided by increased capacity and favourable payment terms; the market is dominated by MIGS products which in 2025 generated $0.65 billion in sales, and reflects a shift towards less invasive glaucoma surgery techniques that reduce recovery time and side effects and can also be used in conjunction with cataract surgery; improvements in micro stent design, imaging techniques used during surgery and safer implant materials are ensuring that the treatment of glaucoma remains a priority for insurance companies, medical professionals and patients who require long term management of their eye pressure.

Surgical glaucoma devices comprise devices designed to decrease intraocular pressure, this equipment consists of glaucoma drainage implants, trabecular meshwork bypass systems, and micro stents. Key characteristics of this device are its precision and ability to be combined with the phacoemulsification process. This glaucoma device is utilised for treating secondary and mild to severe glaucoma conditions. These glaucoma devices are generally utilised in operating theatres and private clinics where eye surgeons use them for their standalone and combined operations, their aim is to keep the intraocular pressure at a stable level and help in preserving vision. Glaucoma surgical devices demand is boosted by an increasing number of early treatments. The increase in use of surgical glaucoma devices rather than eye drops and the increasing variety of new glaucoma drainage technologies that can treat glaucoma are driving demand.

Glaucoma Surgery Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Glaucoma Surgery Devices Market Outlook

Market Key Insights

  • Projected market value for glaucoma surgery equipment is $1.4 billion by 2024 and will reach $2.7 billion by 2034. At a 6.7% compound annual growth rate, there is a rising demand for this product in Hospital eye care, ophthalmic clinics and ambulatory surgical centres.

  • Among the key players in this sector are Glaukos, Alcon and Johnson and Johnson Vision, with their activities defining the market landscape.

  • The US and China represent the most significant markets in the glaucoma surgery devices sector. These countries will experience a growth rate ranging from 4.4% to 6.4% from 2024 to 2030.

  • The highest growth rates are expected to be seen in the emerging markets of India, Brazil and South Korea, with a Compound Annual Growth Rate ranging from 7.7% to 9.2%.

  • Transition to minimally invasive surgery techniques is expected to have a substantial impact on the U.S. and China markets within the value chain. By 2030, the Glaucoma Surgery Devices market should see $62 million of extra revenue.

  • Between 2024 and 2034 the Glaucoma Surgery Devices market is projected to be worth $1.3 billion. The Glaucoma Surgery Devices industry will see the manufacturers focusing on sales to Ophthalmic clinics and ambulatory surgery centres.

  • With

    rising global glaucoma prevalence and expanding adoption of minimally invasive procedures in ophthalmic surgical practice, and

    Technological innovation in microstent technology enhancing long-term intraocular pressure control and safety profiles, Glaucoma Surgery Devices market to expand 91% between 2024 and 2034.

glaucoma surgery devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Glaucoma Surgery Devices - Country Share Analysis

Opportunities in the Glaucoma Surgery Devices

The expanding healthcare systems in Asia create a considerable opportunity for glaucoma surgery products as they extend insurance coverage for an ageing population along with diabetes related eye complications. Though a number of hospitals are also now upgrading their ophthalmic surgical facilities, the use of glaucoma drainage devices and minimally invasive glaucoma surgery remains limited in China outside major cities. The areas of secondary and rural locations are anticipated to exhibit above average growth in surgical procedures, specifically in the case of drainage devices and MIGS implants utilised in outpatient glaucoma surgery. As a result, drainage based systems will probably do better than conventional surgical instruments in the next decade.

Growth Opportunities in North America and Asia-Pacific

The demand in North America for glaucoma surgery devices is driven by high volumes of operations, the fact that procedures are well reimbursed and there is an advanced system for outpatient care. This has led to the surgical centres which are open to the public, known as Ambulatory Surgery Centres, being the most influential customers as they prioritise procedures which may be performed quickly in conjunction with cataract surgery. A procedure pack designed specifically for ASCs, devices which are used once and then discarded to relieve glaucoma and expensive glaucoma drainage implants which have been shown to reduce the risk of complications and reduce the time taken in theatre are the best opportunities. Competition is fierce between the manufacturers of medical equipment who are well established as they use clinical data, provide training for surgeons and integrate with digital theatre systems to differentiate themselves.
The primary factor behind the adoption of glaucoma surgery equipment in the Asia Pacific is better healthcare coverage, a growing public awareness of glaucoma and investments in hospitals which specialise in eye care. Consequently hospitals with large facilities are the key buyers of these devices because they undertake complex surgery and have the resources to purchase advanced laser and implant equipment; opportunities for the glaucoma surgery devices include sales of cost effective devices alongside more expensive minimally invasive systems to both private and public hospitals, supporting high volume centres with training and maintenance and forming alliances with national eye health schemes. The market for these devices is competitive with companies offering innovative products alongside lower priced regional manufacturers, as a result manufacturers have to balance the cost of their products with their durability, ease of use and compatibility with other equipment.

Market Dynamics and Supply Chain

01

Driver: Rising global glaucoma prevalence and expanding adoption of minimally invasive procedures in ophthalmic surgical practice

The growing incidence of glaucoma due to an aging population, rising diabetes levels and higher levels of myopia is also expanding the market for glaucoma surgical equipment. Early surgical intervention is also recommended to halt further deterioration in the condition of patients at high risk of losing their sight. In such individuals surgery can also replace the treatments of laser therapy and medication. Currently the high adoption rate of minimally invasive glaucoma surgery is also influencing the choice of procedure in clinics as well as in hospitals. Conventional surgical equipment for trabeculectomies is also being replaced by micro trabeculectomy implants and procedures that are also based on the angle of the eye. These advancements allow for quicker recovery times along with a decrease in surgical complications and a better quality of life for the patient. The recent trend is also expected to increase demand for more advanceds of glaucoma drainage devices and for ophthalmic implants suited to the treatment of milder or moderate cases of the disease. This development is also also helping to introduce standard procedures and training programmes. These trends collectively contribute to sustained volume growth and to the diversification of products for leading manufacturers.
Recent advancements in micro stent technology mean glaucoma surgery equipment can also result in a more stable and prolonged lowering of eye pressure with less after effects following surgery. Research into novel lumen geometries, enhanced biocompatible coatings, and the use of ab interno delivery systems is also aiming to reduce tissue damage and improve the outflow of aqueous humour. In order to make their products applicable to a wider range of glaucoma cases and also to prevent the risk of hypotony, manufacturers are also incorporating micro scale regulation of fluid flow into the devices. The performance gains which these systems offer along with simplified application techniques and shorter learning curves are also now encouraging more surgeons to adopt these systems and are also being included in clinical guidelines. Evidence that is also clinical is also showing that micro stent systems of the latest are also crucial to the methods of managing glaucoma that are also used in the long term, thereby facilitating premium pricing and repeat surgeries.
02

Restraint: High procedural costs and reimbursement uncertainties restrict widespread adoption of advanced glaucoma surgery devices worldwide

The high cost of glaucoma surgery equipment, including equipment used for minimally invasive glaucoma surgery and glaucoma implants, coupled with the uncertainty of reimbursements in hospitals and clinics, makes many glaucoma treatments too expensive. Consequently, doctors prefer the use of cheaper treatments such as laser surgery or drugs over devices to control eye pressure. As a result of this, the number of procedures and revenue in ophthalmic device markets are slowing down. The delayed reimbursement of products has led to a freeze on procurement in some regions of the developed world. This has resulted in a prolonged replacement cycle for glaucoma devices and led to a lower average selling price. As a result of this manufacturers have had to offer discounts in order to sell products.
03

Opportunity: Deployment of connected glaucoma surgery drainage devices in value based hospital networks across Western Europe and Scaling demand for laser based glaucoma surgery devices in high volume ophthalmology clinics across North America

Healthcare providers in the Western European region who operate a network of hospitals are currently looking for medical technology that allows glaucoma surgery to be performed with the goal of reducing costs. This device must link up with the hospitals electronic medical record systems. This leads to intelligent glaucoma drainage devices capable of continuous assessment of outflow and reporting of the data. This helps in better control of the patient after surgery and a decrease in the number of readmissions. By 2030, the global market for drainage devices is forecast to reach $0.43 billion, an increase from $0.30 billion in 2025, with a compound annual growth rate of 7.16%. The drainage implant market is expected to grow faster than the markets for surgical instruments and laser systems.
High volume clinics in North America are more frequently beginning to use laser glaucoma therapy machines which allow easier control of intraocular pressure and help reduce treatment side effects. The availability of reimbursement support for procedures that are non invasive has led to a preference for lasers over incisional surgical techniques. The market for laser systems in the treatment of glaucoma surgery is expected to grow at a compound annual growth rate of 7.8% between 2025 and 2030. The market value in 2025 was $0.65 billion and by 2030 it will be $0.94 billion. This represents the fastest growth of any category within glaucoma surgery devices in developed countries.
04

Challenge: Limited surgeon training and steep learning curves slow clinical uptake of innovative glaucoma surgery devices

Because training in advanced minimally invasive glaucoma surgery techniques is required to utilise new generation glaucoma surgical devices, the use of the more advanced devices is limited. Although high tech equipment is safe as studies have shown, a lack of the relevant hands on experience among clinicians lowers their confidence in its usage. This in turn means these technologies are used too little. In practice, several care facilities have taken advantage of new glaucoma drainage devices; however, many community hospitals continue to prefer traditional trabeculectomy and drainage methods, leading to uneven market demand, suboptimal device penetration and revenue expansion problems for companies seeking wider integration of these devices in the medical field.

Supply Chain Landscape

1

Ophthalmic Surgical Devices

DSM BiomedicalZeiss MeditecBausch + Lomb
2

Glaucoma Surgery Devices

Glaukos CorporationAlconJohnson & Johnson Vision
3

MIGS Implants

McKessonCardinal HealthAmerisourceBergen
4

Intraocular Pressure Management

HospitalsOphthalmology clinicsMinimally invasive glaucoma surgery centers
Glaucoma Surgery Devices - Supply Chain

Use Cases of Glaucoma Surgery Devices in Hospital Eye Care & Ambulatory Centers

Hospital Eye Care : Glaucoma surgery devices help healthcare professionals in managing complex cases of glaucoma. This industry is forecast to expand at an annual rate of 6.4% from 2026, reaching 0.86 billion dollars by 2025. Glaucoscopy facilities incorporate a full range of drainage devices and surgical equipment; laser systems with about 46.3% of the equipment demand are used in procedures which involve laser trabeculoplasty to decrease pressure inside the eye, and drainage devices which represent approximately 21.5% are used in eye operations where pressure inside the eye is raised. Well known in the healthcare industry for developing glaucoma surgical techniques requiring minimal invasion and innovative glaucoma implants, Glaukos Corporation has established itself as a leader. Strong positions are held by Alcon and Johnson & Johnson Vision, through the manufacture of surgical instruments and laser platforms for ophthalmology, along with comprehensive support networks; Abbott Laboratories uses its integrated diagnostic and surgical products to assist hospital staff in their treatment of glaucoma, by providing streamlined glaucoma care routes; in addition Allergan uses its range of glaucoma management products, including implants, to help maintain pressure in the eye in the long term.
Ophthalmic Clinics : Glaucoma surgeries which are carried out on a large scale are the core of the work of ophthalmic clinics. Equipment for glaucoma surgery in these clinics is geared towards efficiency and precision. By 2025 it will generate revenues of nearly 0.31 billion USD and is expected to grow at a rate of 7.3% annually until 2030. These clinics employ compact lasers in procedures such as laser trabeculoplasty and laser iridotomy, along with ophthalmic surgical instruments designed with ergonomics in mind and other minimally invasive glaucoma surgical equipment that enables earlier treatment and less medication over time. Leading companies in this region include Alcon with its clinic optimised laser platforms and integrated diagnostic surgical treatment systems, Glaukos Corporation with its minimally invasive glaukos products which can be used alongside clinic and surgical center services, Johnson & Johnson Vision who offer a broad range of ophthalmic products and services to support continuum of care models, Abbott with its advanced diagnostic equipment which can be used to guide timely device based interventions and Allergan who use their strong glaucoma therapy to create combined medical and surgical management strategies.
Ambulatory Surgery Centers : Centres for day case eye surgery are rapidly becoming a crucial route for the sale of equipment used in the treatment of glaucoma. By 2025 this is expected to generate $0.16 billion. The growth rate is expected to be 7.6% annually from 2026 to 2030. They make use of compact laser systems, disposable surgical instruments designed for eye surgery and cost effective glaucoma surgery devices to provide a cataract and glaucoma surgery which is minimally invasive. This allows for quicker patient recovery and faster turnover, which enhances their appeal over traditional hospital treatments.

Recent Developments

Developments in glaucoma surgery equipment are at present aimed at a less invasive procedure for glaucoma surgery, new microstents and more sophisticated drainage implants. These developments improve control of intraocular pressure while minimising complications. To improve the predictability and safety of glaucoma surgeries, the development of new glaukos surgical equipment is underway. This new equipment combines two technologies, micro invasive surgery and image guided systems. Combined cataract and glaucoma surgery is becoming increasingly popular due to reimbursement packages that cover these procedures and the wealth of data supporting its safety and efficacy.

December 2023 : Glaukos has received US FDA approval for its minimally invasive glaucoma surgical device. iDose TR is an intraocular pressure reducing implant given in adults with ocular hypertension or glaucoma via a procedure called an ab interno procedure. This development is expected to allow the glaucoma surgery devices market to increase due to Glaukos products. This is a result of ophthalmic surgical devices being more effective than other glaucoma devices.
April 2023 : The FDAs approval of Glaukos new drug application for its iDose TR implant for glaucoma has meant that Glaukos can now accelerate surgeon training, clinical education and pre commercialisation activities. This move shows the US FDAs increased confidence in glaucoma treatment implants which release medication slowly. This will give the market for glaucoma treatment more investment from companies who make ophthalmic devices.

Impact of Industry Transitions on the Glaucoma Surgery Devices Market

As a core segment of the Medical Device industry, the Glaucoma Surgery Devices market develops in line with broader industry shifts. Over recent years, transitions such as Rapid Shift To Minimally Invasive and Data Driven And Outpatient Care have redefined priorities across the Medical Device sector, influencing how the Glaucoma Surgery Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Rapid Shift To Minimally Invasive

The transition from conventional trabeculectomies to minimally invasive glaucoma surgery is reshaping the glaucoma surgery devices market, particularly in the U.S. and China, where this shift is projected to generate an additional $62 million in revenue by 2030. The demand for advanced devices such as microstents, canaloplasty systems, and ab interno glaucoma drainage implants is driving distributors and surgical units to adopt integrated treatment systems. This evolution not only transforms the ophthalmic surgical equipment landscape but also compels suppliers of surgical visual aids, intra operative diagnostic tools, and disposable instruments to innovate their offerings. As MIGS becomes increasingly integrated with cataract surgery, the entire value chain is poised for significant growth, underscoring the strategic importance of adapting to these emerging surgical techniques.
02

Data Driven And Outpatient Care

The trend towards inpatient glaucoma surgery being replaced by day case image guided procedures is raising the bar for glaucoma surgery equipment. This is particularly so regarding their intraocular pressure management and connectivity with digital systems. The interoperability of the eye care markets data systems enables diagnostics, surgical planning and post operative monitoring to be linked together. The move is affecting health IT vendors, companies providing remote monitoring services and telemedicine providers of eye care, and they are being forced to incorporate real time device data into their systems. Meanwhile, value based healthcare initiatives are revamping payment procedures. This is being done in an effort to make them more focused on value and quality, rather than just the volume of procedures performed.